United Therapeutics (UTHR) Other Non-Current Assets (2009 - 2026)

United Therapeutics has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $239.5 million for Q2 2026.

• In Q2 2026, Other Non-Current Assets rose 2.66% year-over-year to $239.5 million; the TTM figure through Jun 2026 stood at $239.5 million (up 2.66% YoY), while the FY2025 annual figure was $196.9 million, down 11.35% from the prior year.
• Other Non-Current Assets came in at $239.5 million for Q2 2026 at United Therapeutics, up from $233.2 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $262.6 million in Q3 2025 to a low of $105.8 million in Q2 2022.
• Average Other Non-Current Assets over 5 years is $174.0 million, with a median of $168.5 million recorded in 2024.
• Year-over-year, Other Non-Current Assets tumbled 40.23% in 2022 and soared 46.31% in 2024.
• Over 5 years, Other Non-Current Assets stood at $114.3 million in 2022, then soared by 32.81% to $151.8 million in 2023, then soared by 46.31% to $222.1 million in 2024, then fell by 11.35% to $196.9 million in 2025, then rose by 21.64% to $239.5 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $239.5 million in Q2 2026, $233.2 million in Q1 2026, and $196.9 million in Q4 2025.